Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1989 4
1990 2
1991 2
1992 3
1993 4
1994 1
1995 1
1997 1
1998 2
1999 2
2000 1
2001 3
2003 3
2005 1
2006 2
2007 1
2008 2
2009 2
2010 1
2011 2
2012 1
2013 4
2014 3
2015 2
2016 4
2017 4
2018 7
2019 7
2020 5
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

75 results
Results by year
Filters applied: . Clear all
Page 1
Telmisartan, ramipril, or both in patients at high risk for vascular events.
ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. ONTARGET Investigators, et al. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31. N Engl J Med. 2008. PMID: 18378520 Free article. Clinical Trial.
De novo mutations in ATP1A3 cause alternating hemiplegia of childhood.
Heinzen EL, Swoboda KJ, Hitomi Y, Gurrieri F, Nicole S, de Vries B, Tiziano FD, Fontaine B, Walley NM, Heavin S, Panagiotakaki E; European Alternating Hemiplegia of Childhood (AHC) Genetics Consortium; Biobanca e Registro Clinico per l'Emiplegia Alternante (I.B.AHC) Consortium; European Network for Research on Alternating Hemiplegia (ENRAH) for Small and Medium-sized Enterpriese (SMEs) Consortium, Fiori S, Abiusi E, Di Pietro L, Sweney MT, Newcomb TM, Viollet L, Huff C, Jorde LB, Reyna SP, Murphy KJ, Shianna KV, Gumbs CE, Little L, Silver K, Ptáček LJ, Haan J, Ferrari MD, Bye AM, Herkes GK, Whitelaw CM, Webb D, Lynch BJ, Uldall P, King MD, Scheffer IE, Neri G, Arzimanoglou A, van den Maagdenberg AM, Sisodiya SM, Mikati MA, Goldstein DB. Heinzen EL, et al. Among authors: herkes gk. Nat Genet. 2012 Sep;44(9):1030-4. doi: 10.1038/ng.2358. Epub 2012 Jul 29. Nat Genet. 2012. PMID: 22842232 Free PMC article.
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, et al. Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Epub 2008 Aug 29. Lancet. 2008. PMID: 18757085 Clinical Trial.
Immune mediated neuropathy following checkpoint immunotherapy.
Gu Y, Menzies AM, Long GV, Fernando SL, Herkes G. Gu Y, et al. Among authors: herkes g. J Clin Neurosci. 2017 Nov;45:14-17. doi: 10.1016/j.jocn.2017.07.014. Epub 2017 Jul 29. J Clin Neurosci. 2017. PMID: 28765062 Review.
Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study.
Langhorne P, O'Donnell MJ, Chin SL, Zhang H, Xavier D, Avezum A, Mathur N, Turner M, MacLeod MJ, Lopez-Jaramillo P, Damasceno A, Hankey GJ, Dans AL, Elsayed A, Mondo C, Wasay M, Czlonkowska A, Weimar C, Yusufali AH, Hussain FA, Lisheng L, Diener HC, Ryglewicz D, Pogosova N, Iqbal R, Diaz R, Yusoff K, Oguz A, Wang X, Penaherrera E, Lanas F, Ogah OS, Ogunniyi A, Iversen HK, Malaga G, Rumboldt Z, Magazi D, Nilanont Y, Rosengren A, Oveisgharan S, Yusuf S; INTERSTROKE collaborators. Langhorne P, et al. Lancet. 2018 May 19;391(10134):2019-2027. doi: 10.1016/S0140-6736(18)30802-X. Epub 2018 May 17. Lancet. 2018. PMID: 29864018
75 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page